Effect of sodium-glucose Co-transporter 2 inhibitors on coronary microcirculation
Frontiers in PharmacologyCoronary microvascular disease (CMVD) has emerged as a new target for the occurrence and development of heart failure treatment. Various indicators such as Index of Microvascular Resistance, Coronary Flow Reserve, Microvascular Resistance Reserve ...
Shaoxin Chen +5 more
doaj +3 more sources
Research advances on renoprotective mechanism of SGLT-2 inhibitors in non-diabetic kidney disease
Linchuang shenzangbing zazhi, 2023 Sodium-glucose linked transporter (SGLT-2) inhibitors are the most emerging glucose-lowering agents. Predominantly expressed in kidney, SGLT-2 is mainly distributed in upper part of proximal tubule.
Feng Liu +3 more
doaj +1 more source
Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2022 Background Although cardiovascular outcome trials using sodium-glucose cotransporter-2 inhibitors (SGLT-2i) showed a reduction in risk of 3-point major adverse cardiovascular events (MACE), they did not demonstrate beneficial effects on stroke risk ...
Seung Eun Lee +5 more
doaj +1 more source
Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
Frontiers in Pharmacology, 2022 Arrhythmias are clinically prevalent with a high mortality rate. They impose a huge economic burden, thereby substantially affecting the quality of life.
Yuling Jing +3 more
doaj +1 more source
Sodium-glucose co-transporter 2 inhibitors – a review article
Journal of Education, Health and Sport, 2019 Antihyperglycemic interventions have centered on increasing insulin availability, improving insulin sensitivity or restoring β-cell activity to normalize plasma glucose levels in patients with type 2 diabetes mellitus.
Marcin Makuch +3 more
doaj +3 more sources
Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea [PDF]
Endocrinology and Metabolism, 2020 Background We assessed the glucose-lowering efficacy of adding empagliflozin versus dose escalating existing medications in patients with uncontrolled type 2 diabetes (T2D).
Yujin Shin +4 more
doaj +1 more source
Клинический разбор в общей медицине, 2021 The diabetic ketoacidosis (DKA) is the most frequent urgent condition in patients with diabetes mellitus which requires hospitalization and results to mortality. The most common causes of DKA are the presence of concomitant diseases in diabetic patients,
Diana Sh. Avzaletdinova +3 more
doaj +1 more source
Genito-urinary infection risk estimates during sodium glucose co-transporter 2 inhibitor exposure in everyday clinical practice. [PDF]
Farmacja Polska, 2021 Genito-urinary infection risk estimates during sodium glucose co-transporter 2 inhibitor exposure in everyday clinical practice. Type 2 diabetes mellitus, cardiovascular diseases and congestive heart failure are known to be a cause of growing ...
Beata Jacuś +3 more
doaj +1 more source
SGLT2 Inhibitors for Nephrologists
European Medical Journal Nephrology, 2022 Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are the mainstay of therapy for the prevention of progressive renal damage in diabetic and non-diabetic kidney diseases, especially glomerulonephritides.
Mufti Baleegh-ur-Raheem Mahmood +1 more
doaj +1 more source
Pharmaceutics, 2023 Type 2 diabetes mellitus is a major health problem worldwide with a steadily increasing prevalence reaching epidemic proportions. The major concern is the increased morbidity and mortality due to diabetic complications.
Melpomeni Peppa +7 more
doaj +1 more source